Table 3.
Best overall response by independent central review per RECIST v1.1.
| Pembrolizumab 200 mg Q3W | Pembrolizumab 200 mg Q3W | |
|---|---|---|
| + ipilimumab 50 mg Q6W | + ipilimumab 100 mg Q12W | |
| (n = 51) | (n = 51) | |
| Objective response rate | ||
| N | 28 | 31 |
| % (95% CIa) | 55 (40–69) | 61 (46–74) |
| Best overall response, n (%) | ||
| Complete response | 8 (16) | 13 (25) |
| Partial response | 20 (39) | 18 (35) |
| Stable disease | 10 (20) | 8 (16) |
| Progressive disease | 8 (16) | 5 (10) |
| Disease not measurable per central review at baseline, that did not completely resolve or progress | 2 (4) | 5 (10) |
| Non-evaluable | 1 (2) | 1 (2) |
| No assessment done | 2 (4) | 1 (2) |
| Time to response in months, median (range) | 1.4 (1.3–8.3) | 1.5 (1.3–10.9) |
| Duration of response in months, median (range) | Not reached (1.4+ to 17.9+) | Not reached (2.8+ to 18.3+) |
Abbreviations: Q3W, every 3 weeks; Q6W, every 6 weeks; Q12W, every 12 weeks; RECIST v1.1, Response Evaluation Criteria in Solid Tumors, version 1.1.
aBased on binomial exact confidence interval method.